Harvard-MIT Division of Health Sciences and Technology, Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139.
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139.
Proc Natl Acad Sci U S A. 2022 Jun 21;119(25):e2121778119. doi: 10.1073/pnas.2121778119. Epub 2022 Jun 13.
Community-acquired pneumonia (CAP) has been brought to the forefront of global health priorities due to the COVID-19 pandemic. However, classification of viral versus bacterial pneumonia etiology remains a significant clinical challenge. To this end, we have engineered a panel of activity-based nanosensors that detect the dysregulated activity of pulmonary host proteases implicated in the response to pneumonia-causing pathogens and produce a urinary readout of disease. The nanosensor targets were selected based on a human protease transcriptomic signature for pneumonia etiology generated from 33 unique publicly available study cohorts. Five mouse models of bacterial or viral CAP were developed to assess the ability of the nanosensors to produce etiology-specific urinary signatures. Machine learning algorithms were used to train diagnostic classifiers that could distinguish infected mice from healthy controls and differentiate those with bacterial versus viral pneumonia with high accuracy. This proof-of-concept diagnostic approach demonstrates a way to distinguish pneumonia etiology based solely on the host proteolytic response to infection.
由于 COVID-19 大流行,社区获得性肺炎(CAP)已成为全球卫生重点关注的问题。然而,病毒性肺炎与细菌性肺炎病因的分类仍然是一个重大的临床挑战。为此,我们设计了一组基于活性的纳米传感器,用于检测与引起肺炎的病原体反应相关的肺部宿主蛋白酶的失调活性,并产生疾病的尿读数。纳米传感器的靶点是根据从 33 个独特的公开研究队列中生成的用于肺炎病因的人类蛋白酶转录组特征选择的。开发了五种细菌性或病毒性 CAP 的小鼠模型,以评估纳米传感器产生病因特异性尿特征的能力。使用机器学习算法训练诊断分类器,能够区分感染小鼠和健康对照,并且能够高精度地区分细菌性肺炎和病毒性肺炎。这种概念验证诊断方法展示了一种仅基于感染后宿主蛋白酶反应来区分肺炎病因的方法。